Lupin Ltd

Mid Cap

Healthcare Sector

reflects a positive outlook for the share price

reflects a neutral outlook for the share price

reflects a negative outlook for the share price

The analysts information is for reference only and does not\n  represents an investment recommendation.

Analyst recommendation reflect the views of analysts who follow and write research reports.

Company Information is an introduction to the company’s business that details what it sell, how it was founded, what their mission is, how they manufacture or source their products, and why they serve customers.

Lupin Ltd is actively expanding its operations with new corporate offices in New Jersey while facing a decline in stock price for five consecutive sessions. Additionally, ongoing clinical studies on Mexiletine aim to enhance treatment options for myotonic disorders.

Lupin Ltd Expands Operations Amidst Stock Decline - 28 Oct, 2025

The Directorate General of Trade Remedies has launched an investigation into tuberculosis drug imports from China and Thailand, prompted by Lupin Ltd's allegations of unfair pricing practices.

Lupin's Petition Triggers Anti-Dumping Investigation - 27 Oct, 2025

Lupin Limited has launched an authorized generic version of Ravicti Oral Liquid in the U.S., aimed at managing urea cycle disorders. This strategic move enhances Lupin's presence in the U.S. pharmaceutical market.

Lupin Launches Authorized Generic Drug in U.S. - 24 Oct, 2025

Lupin announced that the U.S. FDA's pre-approval inspection at its Somerset, New Jersey facility concluded with one observation. The company is committed to addressing this promptly.

Lupin's FDA Inspection Concludes with One Observation - 11 Oct, 2025

Lupin plans to invest $250 million in a new pharmaceutical manufacturing facility in Coral Springs, Florida, to produce over 25 critical respiratory medicines, including albuterol inhalers. This project will create over 200 skilled jobs by 2030 and enhance medicine security in the U.S.

Lupin Invests $250 Million in Florida Facility - 08 Oct, 2025

Lupin's Pithampur Unit-2 received a Form-483 with four observations from the USFDA, classified as Official Action Indicated. Despite this, Lupin launched Liraglutide Injection in the U.S., marking a significant portfolio expansion.

Lupin Faces Regulatory Challenges Amid New Product Launch - 04 Oct, 2025

Lupin has launched Liraglutide injection in the US for type 2 diabetes, marking a significant portfolio enhancement. Axis Securities forecasts a 26% upside for the stock.

Lupin Launches New Injection, Stock Target Raised - 03 Oct, 2025

Lupin has made significant strides by acquiring VISUfarma for Euro 190 million, enhancing its ophthalmic portfolio, and receiving US FDA approval for pediatric Rivaroxaban oral suspension.

Lupin Secures FDA Approval and Acquires VISUfarma - 30 Sep, 2025

Lupin Ltd's subsidiary, Nanomi B.V., has signed an agreement to acquire VISUfarma B.V. for €190 million, aiming to strengthen its position in the growing European ophthalmology market. The deal is expected to close by the end of 2025, pending regulatory approvals.

Lupin Subsidiary Acquires VISUfarma for €190 Million - 29 Sep, 2025

Price to Earnings Ratio or Price to Earnings Multiple is the ratio of the share price of a stock to its earnings per share (EPS). It provides an indication of whether a stock at its current market price is expensive or cheap.

The price/earnings-to-growth ratio, or the PEG ratio, is a metric that helps investors value a stock by taking into account a company's market price, its earnings, and its future growth prospects.

Enterprise value (EV) is the total value of a company, defined in terms of its financing. It includes both the current share price (market capitalization) and the cost to pay off debt (net debt, or debt minus cash).

Alpha measures the amount that the investment has returned in comparison to the market index or other broad benchmark that it is compared against.

Beta measures a stock's volatility, the degree to which its price fluctuates in relation to the overall stock market. In other words, it gives a sense of the stock's risk compared to that of the greater market.

Dividend yield measures the quantum of earnings by way of total dividends that investors make by investing in that company.

The debt-to-total-assets ratio shows how much of a business is owned by creditors (people it has borrowed money from) compared with how much of the company's assets are owned by shareholders.

Operating cash flow (OCF) is a measure of the amount of cash generated by a company's normal business operations. Operating cash flow indicates whether a company can generate sufficient positive cash flow to maintain and grow its operations.

This widget shows the information about the stock's peers in consideration along with the different data for those peers so that the user can compare the stock with the other similar stock and invest accordingly.

Promoter holding is the amount of share of the company that is owned by the promoters. The promoters are the company's founders, who hold a majority stake in the company's capital.

A foreign institutional investor (FII) is an investor or investment fund investing in a country outside of the one in which it is registered or headquartered.

A mutual fund is a pool of money managed by a professional Fund Manager. It is a trust that collects money from a number of investors who share a common investment objective and invests the same in equities, bonds, money market instruments, and other securities.

Retail investors execute their trades through traditional or online brokerage firms or other types of investment accounts. Retail investors purchase securities for their own personal accounts and often trade in dramatically smaller amounts as compared to institutional investors.

This widget shows the bifurcation of stocks based on the percentage of stake with the different types of shareholders.

This widget will help value the stock based on the Price to Earning ratio of the stock and compare the valuation with the industry value and other similar stocks. It even shows the timeline of the valuation of the stock and its highest and lowest valuation over time.
A Time Series data is provided which compares the historical stock PE with Industry PE over the period of 5 years.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

Revenue is up for the last 2 quarters, 5.72K Cr → 6.34K Cr (in ₹), with an average increase of 9.8% per quarter

This section gives you an insight into how the revenue of the company has moved for the last few quarters.

Revenue Rich

In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals

This section gives you an insight into why this company has been the best in its industry for the last 3 years.

Best in 3 Years

Mutual Funds have increased holdings from 19.35% to 20.57% in Sep 2025 quarter

This section gives you an insight into how the Mutual Funds Holding has changed for the stock over last few quarters.

MF Holding Up

In the last 7 days, LUPIN stock has moved up by 3.4%

This section gives you an insight into the price movement of the stock for the last few quarters.

Price Rise

Netprofit is up for the last 2 quarters, 772.52 Cr → 1.21K Cr (in ₹), with an average increase of 36.6% per quarter

This section gives you an insight into how the profit for the company has been for the last few quarters.

Profit Spike

Promoters holdings remained unchanged at 46.90% of holdings in Sep 2025 quarter

This section gives you an insight into how the Promoter Holding has changed for the stock over the last few quarters.

Promoter Holding Unchanged

In the last 1 year, Divis Laboratories Ltd has given 15.3% return, outperforming this stock by 24.6%

This section gives you an insight into how the peers have performed as compared to this company in the last 1 year.

Against Peers

Foreign Institutions have decreased holdings from 21.25% to 20.49% in Sep 2025 quarter

This section gives you an insight into how the FII Holding has changed for the stock over last few quarters.

FII Holding Down

Retail Investor have decreased holdings from 6.28% to 6.06% in Sep 2025 quarter

This section gives you an insight into how the Retail Investors Holding has changed for the stock over last few quarters.

Retail Holding Down

Nifty Midcap Liquid 15

Nifty Midcap Sel

NIFTY PHARMA

S&P BSE Largecap

BSE 100

Nifty Healthcare

S&P BSE SEN. N50

Nifty Midcap 100

Nifty Midcap 50

S&P BSE 100 ESG

Nifty 200

S&P BSE 250 LargeMidCap

S&P BSE Dividend Stability

S&P BSE 150 MidCap

BSE 200

S&P BSE 400 MidSmallCap

Nifty Midcap 150

Nifty 500

BSE Healthcare

Nifty LargeMidcap 250

BSE 500

Nifty MidSmallcap 400

HDFC Balanced Advantage Fund Direct Plan Growth Option

HDFC Large Cap Fund -Direct Plan - Growth Option

HDFC Flexi Cap Fund -Direct Plan - Growth Option

Mirae Asset Large & Midcap Fund Direct Plan Growth

Nippon India Pharma Fund - Direct Plan - Growth Plan

Lupin Ltd’s net profit jumped 52.13% since last year same period to ₹1,219.03Cr in the Q1 2025-2026. On a quarterly growth basis, Lupin Ltd has generated 57.8% jump in its net profits since last 3-months.

Name	Value	Action
MACD level (12,26)	2.25	Bearish
CCI (20)	-80.68	Neutral
RSI (14)	61.56	Neutral
Momentum (10)	1.4	Bearish
ADI (14)	43.75	Bullish
Ultimate Oscillator (7,14,28)	65.8	Neutral

Name	Value	Action
SMA (20)	1997.97	Bullish
EMA (20)	1997.91	Bullish
VWMA (20)	1998.88	Bullish
SMA (50)	1992.4	Bullish
EMA (50)	1993.52	Bullish
SMA (200)	1987.9	Bullish
EMA (200)	1988.63	Bullish
KAMA (200)	1996.33	Bullish
DEMA (200)	1989.89	Bullish

Lupin Ltd (LUPIN)

Summary

Overall

Oscillators

Moving Averages